心肌无复流防治的最新研究进展(4)
[16] Wang L, Cheng Z, Gu Y, Peng D. Short-term effects of verapamil and diltiazem in the treatment of no reflow phenomenon: a meta-analysis of randomized controlled trials. Biomed Res Int 2015;2015:382086.
[17] Zhao YJ, Fu XH, Ma XX, et al. Intracoronary fixed dose nitroprusside via thrombus aspiration catheter for the prevention of the no-reflow phenomenon following primary percutaneous coronary intervention in acute myocardial infarction.Exp Ther Med 2013;6:479–84.
, 百拇医药
[18] Nazir SA, Khan JN, Mahmoud IZ, et al. The REFLO-STEMI trial comparing intracoronary adenosine, sodium nitroprusside and standard therapy for the attenuation of infarct size and microvascular obstruction during primary percutaneous coronary intervention: study protocol for a randomised controlled trial. Trials 2014;15:371.
[19] Akpek M,Sahin O,Sarli B,et al.Acute Effects of Intracoronary Tirofiban on No-Reflow Phenomena in Patients With ST-Segment Elevated Myocardial InfarctionUndergoing Primary Percutaneous Coronary Intervention[J].Angiology,2015,66(6):560-567
, 百拇医药
[20] Iwakura J, Ito H, Okamura A, et al. Nicorandil treatment in patients with acute myocardial infarction: a meta-analysis. Circ J 2009;73:925–31.
[21] Cung TT, Morel O, Cayla G, et al. Cyclosporine before PCI in patients with acute myocardial infarction. N Engl J Med 2015;373:1021–31.
[22] Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med. 2008;359:473–481.
, 百拇医药
[23] Chakrabarti AK, Feeney K, Abueg G, et al. Rational and design of the EMBRACE STEMI Study: a phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of intravenous Bendavia on reperfu-sion injury in patients treated with standard therapy including primary percuta-neous coronary intervention and stenting for ST-segment elevation myocardial infarction. Am Heart J. 2013;165:509–514.
[24] Lonborg J, Vejlstrup N, Kelbaek H, et al. Exenatide rescues reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2013;33: 1491–1499.
, 百拇医药
[25] Atar D, Petzelbauer P, Schwitter J, et al. Effects of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial. J Am Coll Cardiol. 2009;53(8):720–729.
[26] Zeymer U, Suryapranata H, Monassier JP, et al. The Na+/H+ exchange inhibitor Eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardio-protective effects of eniporide in acute myocardial infarction (ESCAMI) TRIAL. J Am Coll Cardiol. 2001;38(6):1644–1650., 百拇医药(高杰张传焕)
[17] Zhao YJ, Fu XH, Ma XX, et al. Intracoronary fixed dose nitroprusside via thrombus aspiration catheter for the prevention of the no-reflow phenomenon following primary percutaneous coronary intervention in acute myocardial infarction.Exp Ther Med 2013;6:479–84.
, 百拇医药
[18] Nazir SA, Khan JN, Mahmoud IZ, et al. The REFLO-STEMI trial comparing intracoronary adenosine, sodium nitroprusside and standard therapy for the attenuation of infarct size and microvascular obstruction during primary percutaneous coronary intervention: study protocol for a randomised controlled trial. Trials 2014;15:371.
[19] Akpek M,Sahin O,Sarli B,et al.Acute Effects of Intracoronary Tirofiban on No-Reflow Phenomena in Patients With ST-Segment Elevated Myocardial InfarctionUndergoing Primary Percutaneous Coronary Intervention[J].Angiology,2015,66(6):560-567
, 百拇医药
[20] Iwakura J, Ito H, Okamura A, et al. Nicorandil treatment in patients with acute myocardial infarction: a meta-analysis. Circ J 2009;73:925–31.
[21] Cung TT, Morel O, Cayla G, et al. Cyclosporine before PCI in patients with acute myocardial infarction. N Engl J Med 2015;373:1021–31.
[22] Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med. 2008;359:473–481.
, 百拇医药
[23] Chakrabarti AK, Feeney K, Abueg G, et al. Rational and design of the EMBRACE STEMI Study: a phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of intravenous Bendavia on reperfu-sion injury in patients treated with standard therapy including primary percuta-neous coronary intervention and stenting for ST-segment elevation myocardial infarction. Am Heart J. 2013;165:509–514.
[24] Lonborg J, Vejlstrup N, Kelbaek H, et al. Exenatide rescues reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2013;33: 1491–1499.
, 百拇医药
[25] Atar D, Petzelbauer P, Schwitter J, et al. Effects of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial. J Am Coll Cardiol. 2009;53(8):720–729.
[26] Zeymer U, Suryapranata H, Monassier JP, et al. The Na+/H+ exchange inhibitor Eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardio-protective effects of eniporide in acute myocardial infarction (ESCAMI) TRIAL. J Am Coll Cardiol. 2001;38(6):1644–1650., 百拇医药(高杰张传焕)